📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Teva Pharmaceutical Industries Ltd

Common Name
Teva Pharmaceutical Industries
Country
Israel
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
33,892
Ticker
TEVA
Exchange
TEL AVIV STOCK EXCHANGE
Description
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that is predominantly engaged in the development, production, and marketing of generic medicines and specialty pharmaceuticals. I...

Teva Pharmaceutical Industries's GHG Emissions Data Preview

In 2024, Teva Pharmaceutical Industries completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Teva Pharmaceutical Industries has also provided a category-level breakdown for 13 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=TEVA&reporting_period=2024"

Verified Sources Behind Teva Pharmaceutical Industries’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Teva Pharmaceutical Industries’s data sources below and access millions more through our Disclosure Search.

a. Teva Pharmaceutical Industries's ESG Report 2024
a. Teva Pharmaceutical Industries's ESG Report 2024

Insights into Teva Pharmaceutical Industries's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions ofTeva Pharmaceutical Industries amounted to581,573metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Teva Pharmaceutical Industriesdecreased by 1.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Teva Pharmaceutical Industries's Scope 1 Emissions Over Time

201920202021202220232024075 k150 k225 k300 ktCO2e-3%-3%-10%-4%+1%
  • Total Scope 1
  • Year-over-Year Change

What are Teva Pharmaceutical Industries's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Teva Pharmaceutical Industries were 243,603 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

Has Teva Pharmaceutical Industries reduced its Scope 1 emissions over time?

Since 2019, Teva Pharmaceutical Industries's Scope 1 emissions have decreased by 18.57%, reflecting a declining long-term trend in Scope 1 emissions over time.a

Compared to the previous year(2023), Teva Pharmaceutical Industries's Scope 1 emissions remained relatively stable, indicating that Teva Pharmaceutical Industries's emissions have plateaued with no significant change in its operational footprint.a

What are Teva Pharmaceutical Industries's Scope 2 emissions?

In 2024, Teva Pharmaceutical Industries reported Scope 2 greenhouse gas (GHG) emissions of 218,504 tCOâ‚‚e using the market-based method and 337,970 tCOâ‚‚e using the location-based method.a

Has Teva Pharmaceutical Industries reduced its Scope 2 emissions over time?

Compared to the previous year(2023), Teva Pharmaceutical Industries's Scope 2 emissions(Location-Based) have remained relatively stable, indicating that Teva Pharmaceutical Industries's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Teva Pharmaceutical Industries use for Scope 2 reporting?

In 2024, Teva Pharmaceutical Industries reported its Scope 2 emissions using the market-based method and using the location-based method.a

Teva Pharmaceutical Industries's Scope 2 Emissions Over Time

201920202021202220232024090 k180 k270 k360 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Teva Pharmaceutical Industries's Value Chain Emissions

In 2024, Teva Pharmaceutical Industries reported 4,066,116 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Teva Pharmaceutical Industries includes a breakdown across 13of the 15 Scope 3 categories defined by the GHG Protocol,matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Teva Pharmaceutical Industries's Scope 3 Emissions Over Time

2020202120222023202401.5 M3 M4.5 M6 MtCO2e-6%-14%0%-6%
  • Total Scope 3
  • Year-over-Year Change

What are Teva Pharmaceutical Industries's Scope 3 emissions?

In 2024, Teva Pharmaceutical Industries reported total Scope 3 emissions of 4,066,116 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a

Approximately 68.62%of these emissions originated from upstream activities such as purchased goods and capital goods, while 31.38%came from downstream activities like product use, distribution, and end-of-life treatment.a

Compared to the previous year (2023), Teva Pharmaceutical Industries's Scope 3 emissions remained relatively stable, indicating that Teva Pharmaceutical Industries's emissions have plateaued with no significant change in its value chain footprint.a

What categories of Scope 3 emissions does Teva Pharmaceutical Industries disclose?

In 2024, Teva Pharmaceutical Industries reported emissions for 13 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This reflects a high level of granularity and transparency in the company's emissions reporting.

What are the main sources of Teva Pharmaceutical Industries's Scope 3 emissions?

In 2024, the largest contributors to Teva Pharmaceutical Industries's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 2,464,952 tCOâ‚‚e(60.62%)
  • Use of Sold Products (Cat. 11): 754,046 tCOâ‚‚e(18.54%)
  • End-of-Life Treatment of Sold Products (Cat. 12): 470,586 tCOâ‚‚e(11.57%)

Teva Pharmaceutical Industries's Scope 3 Emissions by Categories

Use of Sold Products(Cat. 11)(18.5%)End-of-LifeTreatment of SoldProducts (Cat. 12)(11.6%)Purchased Goods andServices (Cat. 1)(60.6%)

Insights into Teva Pharmaceutical Industries’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Teva Pharmaceutical Industries reported Scope 1 greenhouse gas (GHG) emissions of 243,603 tCOâ‚‚e and total revenues of USD 16,544 millions. This translates into an emissions intensity of 14.72 tCOâ‚‚e per millions USD.a

Teva Pharmaceutical Industries's Scope 1 Emissions Intensity Compared to Peers

2002,00020,000100,0001,000,000Scope 1 Emissions (tCO2e)5001,0005,00010,00050,000Revenues (Millions of USD)CCACHumanwell Healthcare GroupYear: 2024Scope 1: 19,500 tCO2eRevenue: $M 3,485Scope 1 Intensity: 5.60 tCO2e/$MEisaiYear: 2024Scope 1: 45,666 tCO2eRevenue: $M 4,898Scope 1 Intensity: 9.32 tCO2e/$MShionogi & CoYear: 2024Scope 1: 40,090 tCO2eRevenue: $M 2,873Scope 1 Intensity: 13.95 tCO2e/$MGalderma GroupYear: 2023Scope 1: 7,600 tCO2eRevenue: $M 4,117Scope 1 Intensity: 1.85 tCO2e/$MCCChangchun High-TechYear: 2023Scope 1: 61,590 tCO2eRevenue: $M 2,050Scope 1 Intensity: 30.05 tCO2e/$MHikma PharmaceuticalsYear: 2024Scope 1: 38,468 tCO2eRevenue: $M 2,307Scope 1 Intensity: 16.67 tCO2e/$MHansoh Pharmaceutical GroupYear: 2024Scope 1: 13,163 tCO2eRevenue: $M 1,830Scope 1 Intensity: 7.19 tCO2e/$MZydus LifesciencesYear: 2025Scope 1: 56,459 tCO2eRevenue: $M 2,642Scope 1 Intensity: 21.37 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MH LundbeckYear: 2024Scope 1: 20,409 tCO2eRevenue: $M 3,067Scope 1 Intensity: 6.66 tCO2e/$MCiplaYear: 2025Scope 1: 38,283 tCO2eRevenue: $M 3,177Scope 1 Intensity: 12.05 tCO2e/$MGedeon RichterYear: 2024Scope 1: 45,632 tCO2eRevenue: $M 2,171Scope 1 Intensity: 21.02 tCO2e/$MCCChina TCMYear: 2024Scope 1: 104,425 tCO2eRevenue: $M 2,474Scope 1 Intensity: 42.21 tCO2e/$MGlenmark PharmaceuticalsYear: 2025Scope 1: 34,547 tCO2eRevenue: $M 1,539Scope 1 Intensity: 22.45 tCO2e/$MAAAmneal PharmaceuticalsYear: 2024Scope 1: 40,500 tCO2eRevenue: $M 2,794Scope 1 Intensity: 14.50 tCO2e/$MElanco Animal HealthYear: 2024Scope 1: 175,807 tCO2eRevenue: $M 4,439Scope 1 Intensity: 39.61 tCO2e/$MHikari TsushinYear: 2024Scope 1: 1,102 tCO2eRevenue: $M 3,975Scope 1 Intensity: 0.28 tCO2e/$MSwedish Orphan BiovitrumYear: 2024Scope 1: 1,097 tCO2eRevenue: $M 2,362Scope 1 Intensity: 0.46 tCO2e/$MLupinYear: 2025Scope 1: 82,174 tCO2eRevenue: $M 2,597Scope 1 Intensity: 31.64 tCO2e/$MCCChina Resources SanjiuYear: 2024Scope 1: 55,312 tCO2eRevenue: $M 3,784Scope 1 Intensity: 14.62 tCO2e/$MDr Reddy's LaboratoriesYear: 2025Scope 1: 142,772 tCO2eRevenue: $M 3,810Scope 1 Intensity: 37.47 tCO2e/$MSumitomo PharmaYear: 2024Scope 1: 23,101 tCO2eRevenue: $M 2,077Scope 1 Intensity: 11.12 tCO2e/$MBeijing Tong Ren TangYear: 2024Scope 1: 34,974 tCO2eRevenue: $M 2,548Scope 1 Intensity: 13.72 tCO2e/$MTeva Pharmaceutical IndustriesYear: 2024Scope 1: 243,603 tCO2eRevenue: $M 16,544Scope 1 Intensity: 14.72 tCO2e/$M

How does Teva Pharmaceutical Industries's GHG emissions intensity compare to its peers?

In 2024, Teva Pharmaceutical Industries reported a Scope 1 emissions intensity of 14.72 tCOâ‚‚e per millions USD. Compared to the peer group median of 14.5, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Teva Pharmaceutical Industries rank on GHG emissions intensity within its industry?

In 2024, Teva Pharmaceutical Industries ranked 14 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a

Teva Pharmaceutical Industries is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Teva Pharmaceutical Industries's Total Carbon Footprint

In 2024, Teva Pharmaceutical Industries reported a total carbon footprint of 4,647,689 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.37% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Teva Pharmaceutical Industries's total carbon footprint was Scope 3 emissions, accounting for 87.49% of the company's total carbon footprint, followed by Scope 2 emissions at 7.27%.a

Want Full Access to Teva Pharmaceutical Industries's GHG Emissions Dataset?
Sign Up